Watson Pharmaceuticals, the recent acquirer of Andrx, is also being named in the lawsuits.
The lawsuits result from an abbreviated new drug application filed by Andrx for generic versions of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg Adderall XR. Andrx provided notice that it would seek to market its generic products before the expiration of the patent in 2018.
The lawsuits allege that all of Andrx’s generic strengths infringe the patents in suit. Pursuant to legislation, there will be a 30-month stay with respect to Andrx’s proposed generic products.
Shire focuses its business on attention deficit, hyperactivity disorder, human genetic therapies and gastrointestinal and renal diseases.